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Abstract
Diffuse intrinsic pontine glioma (DIPG) is one of the most frequent malignant pediatric brain tumor and its prognosis is
universaly fatal. No significant improvement has been made in last thirty years over the standard treatment with
radiotherapy. To address the paucity of understanding of DIPGs, we have carried out integrated molecular profiling of a
large series of samples obtained with stereotactic biopsy at diagnosis. While chromosomal imbalances did not distinguish
DIPG and supratentorial tumors on CGHarrays, gene expression profiling revealed clear differences between them, with
brainstem gliomas resembling midline/thalamic tumours, indicating a closely-related origin. Two distinct subgroups of DIPG
were identified. The first subgroup displayed mesenchymal and pro-angiogenic characteristics, with stem cell markers
enrichment consistent with the possibility to grow tumor stem cells from these biopsies. The other subgroup displayed
oligodendroglial features, and appeared largely driven by PDGFRA, in particular through amplification and/or novel
missense mutations in the extracellular domain. Patients in this later group had a significantly worse outcome with an
hazard ratio for early deaths, ie before 10 months, 8 fold greater that the ones in the other subgroup (p=0.041, Cox
regression model). The worse outcome of patients with the oligodendroglial type of tumors was confirmed on a series of 55
paraffin-embedded biopsy samples at diagnosis (median OS of 7.73 versus 12.37 months, p=0.045, log-rank test). Two
distinct transcriptional subclasses of DIPG with specific genomic alterations can be defined at diagnosis by oligodendroglial
differentiation or mesenchymal transition, respectively. Classifying these tumors by signal transduction pathway activation
and by mutation in pathway member genes may be particularily valuable for the development of targeted therapies.
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Introduction
Brain tumors are the leading cause of cancer-related morbidity
and mortality in children and adolescents, malignant gliomas
carrying the worst prognosis among them [1]. Malignant gliomas
that diffusely infiltrate the brainstem appear almost exclusively
during childhood and adolescence and have a relatively homog-
enous presentation and dismal prognosis. DIPG represent the
biggest therapeutic challenge in pediatric neuro-oncology with a
median survival of 9 months despite collaborative efforts to
improve treatment [2]. The vast majority of children succumb to
their disease within 2 years of diagnosis. These tumors are
unresectable and radiotherapy is the only treatment offering a
significant but transient improvement. The addition of chemo-
therapy has not shown any benefit over the use of irradiation only
[2,3]. The development of targeted therapies for DIPG has been
hampered by the lack of knowledge of the biology of this
devastating disease. Trials have been implemented so far based on
the assumption that biologic properties of these brainstem gliomas
of children are identical to cerebral high-grade gliomas of adults
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30313[4,5]. Recent data suggest however that pediatric high-grade
gliomas differ from their adult counterparts [6–9], and that there
may be biological distinctions between childhood gliomas
presenting in the brainstem compared with supratentorial ones
[10].
Comprehensive genomic studies of a substantial number of
DIPG at diagnosis have not yet been undertaken due to the lack of
available tumor material. Indeed, diagnosis is usually based on the
association of specific neurological signs, short clinical history with
a typical radiological appearance on MRI [11]. A biopsy is not
needed for diagnosis in most of the cases [12,13]. In addition, most
of these lesions are infiltrating and grading according to the WHO
classification does not correlate with outcome. Accordingly and
despite the reported safety of the procedure [14], most of the
neurosurgical teams limit the use of stereotactic biopsies to the
lesions with unusual clinical or radiological characteristics.
Therefore, only very limited data on true DIPG is available in
the literature and confounded by the inclusion of autopsy – ie post-
radiotherapy - cases [10,15–18].
Recently, our group started to use stereotactic biopsies of DIPG
to obtain both pathological confirmation and immunohistochem-
ical assessment of some specific biomarkers before the inclusion of
patients in trials of targeted agents [19–21]. In this study, we
sought to comprehensively define genetic alterations in DIPG at
diagnosis by performing genome-wide array CGH and gene
expression studies from frozen samples obtained by stereotactic
biopsies. This study is the first to comprehensively define the
biological alterations of DIPG at diagnosis, allowing the discovery
of novel therapeutic targets directed specifically at these poor
prognosis brain neoplasms.
Results
DIPG Biopsy Material
Over the 5 years of the study, 61 patients underwent stereotactic
biopsies taking from one to eight tumor samples (median 3) in the
Neurosurgery Department of Necker Sick Children’s Hospital in
Paris. In most instances, one or two biopsies were used for
histological diagnosis and immunohistochemistry (Figure S1A).
The remaining biopsies were snap-frozen with cytological control
smears directly in the operating room, and nucleic acids extracted
from representative samples. A median of 3.325 microg of DNA
(range 0.805 to 21.5 microg) and 2.332 microg of RNA (range
0.048 to 15.84 microg) could be extracted from the biopsies,
resulting in a total of 32 and 23 patients with sufficient quality and
quantity of DNA and RNA, respectively, for microarray analyses
without any amplification step.
A second set of surgical samples from pediatric non-brainstem
high-grade gliomas of various histologies with arrayCGH (n=34)
and gene expression (n=53) data acquired simultaneously on the
same platform was used for comparative studies. Age distribution
at diagnosis was similar in DIPG and in HGG.
DIPG Differ from Supratentorial High-grade Gliomas but
Co-segregate with a Subgroup of Midline/thalamic
Tumors
We first performed array CGH on the 32 frozen biopsies of
newly diagnosed DIPG, and compared the high resolution DNA
copy number profiles with a series of 34 pediatric supratentorial
high grade gliomas. Unsupervised hierarchical clustering of the
DIPG samples using the Euclidian distance defined two distinct
subgroups, the first characterized by gain of chromosome 1q, and
the second by numerous copy number losses and structural
rearrangements (Figure S1B). There were no associations between
array CGH subgroup and survival, age at onset, duration of
symptoms before diagnosis, radiological characteristics or WHO
grade according to the 2007 revision.
Amplifications at specific loci were detected by CGHarray for
the oncogenes HRAS (5), PDGFRA (4), PDGFB (2), CAV1/2 (2),
PTPRN2 (2), KDM5A (2), ETS1 (1), MYCN (1), WNT2 (1), RAB31
(1). Deletions were detected for PTEN (1), CDKN2A/B (1) and FAS
(1). The oncogene H-RAS was gained or amplified in 7/32 (22%)
and the TP53 tumor suppressor gene was lost in 7/32 (22%) of
cases. Loss of TP53 locus was the only single chromosomal
imbalance associated with a poorer outcome (p=0.01, log-rank
test) (Figure S1C). On immunohistochemistry, p53 overexpression
was seen in 15/27 (55%) cases. A comprehensive list of minimal
common regions of imbalances with a frequency superior to 15%
is provided in Table S1.
It was not possible to clearly delineate DIPG and supratentorial
tumors on the basis of the copy number profiles, as exemplified by
an unsupervised principal component analysis (PCA) generated
using all 42332 quality control passing probes (Figure S1D). By
contrast, a similar PCA analysis of gene expression profiling using
all 15231 quality control passing gene probes demonstrated the
clustering of the DIPG samples distinct from the majority of
supratentorial high-grade gliomas, with the exception of some
midline (thalamic) tumors (Figure 1A).
Supervised analysis using the 76 samples (23 DIPG and 53
HGG) was used to identify the genes most closely associated with
pediatric high-grade gliomas arising in the brainstem versus
supratentorially, and resulted in an expression signature compris-
ing 712 genes (p,0.005, Pearson correlation, Ward procedure)
which could distinguish tumours based on location independent of
WHO grade (Table S2). The corresponding heatmap showed that
the GE profiles of midline tumors clustered in some cases with the
ones of DIPG (Figure 1B). Figure 1C shows the distribution of the
expression for transcription factors and neurogenesis regulators
according to the three different locations. DIPG and supratentorial
tumors could be distinguished by a different pattern of expression
of specific homeobox and HLH genes. When analysing the
expression levels of the major regulators of brainstem embryo-
genesis described in the literature, we observed a significant
upregulation of GAL3ST1, MAFB, OLIG2 and HOXA2,3 and 4 in
DIPG compared to supratentorial tumors (Figure S1E).
DIPG Comprise two Biological Subgroups with Distinct
Survival and Pathological Characteristics
The unsupervised k-means algorithm was used to discover
subgroups of DIPG based on their gene expression profiles. The
most optimal Bayesian Information Criterion (BIC) value was
obtained for the classification based on two clusters [22] (Figure
S2A), as represented by the corresponding principal component
analysis (Figure 2A). Supervised hierarchical clustering identified
643 genes differentially expressed between these two groups (False
Discovery Rate (FDR) adjusted p-value,0.01) (Table S3 and
Figure 2B). The first group had a significantly worse survival, with
70% (9/13) of children succumbing to the disease before the
median overall survival time of 10.6 months (range 2 to 25
months) of the entire cohort, whilst only 10% (1/10) of the patients
in the second group did so (Figure 2C). Since the risk of death was
not proportional over time in the two groups, we use a Cox model
with an interaction between group and time. The hazard ratio for
early deaths, ie before 10 months, was 0.122 for group 2 vs group
1 (p=0.041). Significant association of the 2 GE groups was
observed neither with age nor with the array CGH classification
described above.
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using Spearman correlations demonstrated a significant influence
of copy number on gene expression in group 1 tumours (306/
15189=2% probes significantly correlated), however not for those
in group 2 (3/15189=0.02% probes significantly correlated)
(Figure 2D). These strong correlations were restricted to certain
chromosomal abnormalities, in particular gain of 1q, loss of 19q,
and amplification of 4q12. When considering both groups together
the expression of 1460 genes (6% of the genome) was significantly
correlated with their copy number; six of the twenty most
correlated genes were located on chromosome 4q12 region:
CHIC2, SRP72, CLOCK, PPAT, SRD5A3 and EXOC1 with
Spearman correlation coefficient .0.9 and adjusted p,0.01
(Figure S2B).
Using gene set enrichment analysis [23], the expression profiles
of the two groups were compared with the four subgroups of adult
high grade gliomas recently described as proneural, neural,
classical/proliferative and mesenchymal (http://tcga-data.nci.
nih.goc/docs/publications/gbm_exp/) [24]. The proneural sig-
nature was highly enriched in the gene expression signature of
group 1 (enrichment score=0.66; nominal p=0.004; FDR
q=0.089) (Figure 2E) while the mesenchymal signature was
significantly associated with group 2 tumours (enrichment
score=0.8; nominal p=0.004; FDR q=0.007) (Figure 2F).
Mesenchymal Transition and a Pro-angiogenic Switch
Define A Subset of DIPG
Since a mesenchymal gene expression signature was specifically
represented in one of the two DIPG expression groups, we
compared the expression of 53 transcription factors specific for this
process as previously defined in adult high grade gliomas [25].
These genes were significantly upregulated in the group 2 DIPGs
relative to the group 1 tumours (GSEA analysis: enrichment score
0.56, FDRq=0.039, p nominal=0.034), together with the master
epithelial-mesenchymal transition regulators, SNAI1 and SNAI2/
Slug genes (Figure S3A). Expression of these genes alone was
sufficient to distinguish group 1 and group 2 DIPG (Figure 3A). A
subset of 7 transcription factors (STAT3, BHLHE40, CEBPA and B,
RUNX1, FOSL2 and ZNF238) controlled most genes of the
mesenchymal signature of gliomas; all but ZNF238 were
significantly upregulated in the group 2 tumours compared to
the other DIPG (Figure 3B). This transcriptional module was
associated with a mesenchymal phenotype with upregulation of
TNC, OSMR, VIM and YKL40/CHI3L1 and a more astrocytic
histology (Table S3 & Figures 3A and 3C/D). Knowing that the
BRAF V600E mutations could induce mesenchymal transition in
some tumors [26] and that such mutations have been reported in a
subset of pediatric glioma [27], we sequenced exon 15 of the BRAF
Figure 1. DIPG are different from supratentorial high-grade
gliomas in children. Hemispheric, midline/thalamic tumors and DIPG
are represented in gold, grey and violet respectively. Panel A: Gene
expression of 23 DIPG and 49 supratentorial HGG were compared using
a Principal Component Analysis on all 15231 quality control passing
probes. Tumors are displayed according to their coordinates on the
three first principal components, which describe 29.7% of the variance.
Panel B: Heatmap of the 712 most differentially expressed genes
between DIPG, midline and hemispheric tumors, selected using the
moderated t-test of limma package of Bioconductor. Panel C: Radial
plot of the expression of transcription factors and neurogenesis
regulators according to the three tumor location, in log2 ratios related
to normal brain stem. The zero red line represent the expression level of
normal adult brainstem.
doi:10.1371/journal.pone.0030313.g001
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mutation was detected.
This mesenchymal phenotype was coupled with a hypoxia-
induced angiogenic switch. Numerous proangiogenic genes were
significantly overexpressed in this subgroup of DIPG compared to
the other ones, including VEGFA, VWF, PECAM1, TREM1, OSMR
and PLAU (Table S3 and Figure S3B). There was a strong
correlation between VEGFA and SNAI2/Slug expression
(Figure 3E), and between VEGFA and YKL40 (Figure 3F) across
the entire dataset, with a clear separation of the tumors in the two
groups defined by the gene expression profiling. Endothelial
proliferation was present in 8/9 mesenchymal group 2 tumours vs
8/14 in group 1 (89% vs 57%, p=NS, chi square test). On the
extended cohort of 54 FFPE samples where endothelial prolifer-
ation could be evaluated, there was no correlation with survival,
however an inverse correlation with Olig2 immunopositivity, a
core biomarker of the proneural signature was noted (p=0.01, chi
square test). This angiogenic switch was associated with the
activation of the HIF1A pathway as shown by the higher
expression of HIF1A in group 2 (p=0.058, Student t-test) and
by the significant overexpression compared to group 1 of 5/8 of
the hypoxia-related genes whose promoter is known to be highly
responsive to HIF1A: ENO2, HK1, HK2, LDHA, P4HA2 (Table S3).
This mesenchymal profile was further associated with a
significant overexpression of numerous stem cell markers, including
BMI1, CD34, CD44, CXCR4, LIF, DKK1, VIM and RUNX2,i n
group 2 versus group 1 tumours (Figure S3C). Association of
mesenchymal and stem cell markers was conserved in tumor cells
with stem-like properties derived from three independent DIPG
biopsies. These tumor stem-like cells yielded phenocopies of the
original tumors in intracerebral xenografts (for complete description
see [28]) and had a molecular profile as seen by qPCR similar to
fetal neural stem cells with respect to stem cell markers (ie SOX2,
Musashi1, Nestin and FABP7/BLBP) while overexpressing the
mesenchymal markers YKL40, SNAIL1 and SNAIL2 compared to
normal neural stem cells (Figure 3G). Of note, none of these tumor
stem cells cultures, showed PDGFRA overexpression or amplifica-
tion. The gene expression profile obtained from one of these DIPG
models resembled mesenchymal subtype of DIPG as shown by
unsupervised clustering using PCA (Figure S3D).
Oligodendroglial Differentiation and PDGFRA
Amplification/mutation Define the Remaining Subset of
DIPG
The group 1 of DIPGs as identified by gene expression profiling
was characterized by the overexpression of oligodendroglial
markers compared to group 2 (Figure 4A). Blinded morphological
assessment revealed a significantly greater degree of oligoden-
droglial differentiation in these tumours compared with the
mesenchymal group (Figure 4B and C). Strong expression of
Olig2 by immunohistochemistry was seen in 13/13 tumors in this
group vs 3/8 in group 2 tumours (p value=0.003, chi square test
with McNemar correction) (Figure 4D and E). Of note, SOX10,a
known transcription factor involved in oligodendrogliogenesis
[29,30], was overexpressed in this subgroup compared to the other
DIPG (log2 fold change 1.51 vs 0.21, adjusted p value=0.0018).
We used an extended cohort of 55 patients with histologically
confirmed DIPG to study the impact of oligodendroglial
differentiation on survival. Median overall survival of tumors with
histological oligodendroglial features was 7.73 months versus 12.37
months for tumors that had predominantly astrocytic features
(p=0.045, log rank test) (Figure 4F).
The gene expression profile of group 1 DIPG was significantly
enriched for the gene set describing the signature of PDGFRA
amplified gliomas described in the TCGA [24] and in children
[8] (GSEA analysis: enrichment score 0.59, FDRq=0.038, p
nominal=0.052) (Figure 5A). Although PDGFRA was overex-
pressed in most of the tumors compared to normal brain, this
overexpression was significantly stronger in the group 1 tumours
(p=0.0055) (Figure 4A). This overexpression was confirmed by
immunohistochemistry on an independent cohort in 9/15 cases
that were screened for the target-driven exploratory study of
imatinib in children with solid malignancies [20] (Figure 5B & C).
Eight of nine cases with gain/amplification of PDGFRA detected
by arrayCGH were found in this subgroup; these imbalances
were confirmed by FISH in six samples for which the analysis was
possible (Figure 5D). Simultaneous amplification of PDGFRA and
MET was observed in 4 samples (Figure 5E). A similar
observation of co-amplification of two RTK was observed in
one patient for EGFR and PDGFRA (Figure S4). The minimal
c o m m o nr e g i o no ft h ePDGFRA amplicon also contained LNX1,
RPL21P44, CHIC2, GSK2, KIT and KDR. Integration of copy
number with gene expression data demonstrated a high degree of
correlation only for CHIC2, KIT, KDR and PDGFRA only
(Figure 5F).
Sequencing the PDGFRA gene in an extended series of DIPG
samples revealed no mutations in the kinase domains, known
hotspots in other tumors such as gastro-intestinal stroma tumors
[31]. By contrast, novel missense mutations were observed in the
extracellular domains in 3/34 (8.8%) cases, and in a further two
high grade gliomas established as primary xenografts (Figure 5G).
One of the mutations in the IGRG82 pediatric glioma xenograft
has been previously described in an adult glioblastoma (C235Y)
(http://tcga-data.nci.nih.goc/docs/publications/gbm_exp/). Both
mutant-positive cases for which gene expression data was available
were part of the group 1 DIPG, and harboured PDGFRA gene
amplification, as did the additional case in the extended series.
DIPG subclasses signatures are enriched with genes of
specific neural lineage
We conducted a GSEA to compare the GE profile of the two
groups of DIPG to the gene list generated from 5 neural linages
Figure 2. DIPG are divided into two groups with different gene expression signatures. Gene expression levels of 23 DIPG were analysed
using a unsupervised procedure. Panel A: K-means algorithm followed by a model selection procedure using BIC defined two separated groups of
DIPG that can be also clearly seen with a PCA on all probes that passed the quality control. Panel B: Heatmap of the 643 most differentially expressed
genes between the two groups of DIPG, selected using the moderated t-test of limma package of Bioconductor. Panel C: Overall survival curves of
the two groups of DIPG defining a group of patients who died early (70% of cases before the median survival time of 10.6 months, light green curve)
and a group of patients who died later (90% of cases after the median survival time of 10.6 months, purple curve), (p=0.004, chi-square test). Panel D:
Integrated genomic analysis using DR-Integrator (R package) showing the correlation between probes of copy number and gene expression mapped
on the same genomic coordinates (Refseq HG19) of a gene. In the upper panel (resp. the lower panel), colored vertical lines (cyan for group 1, purple
for group 2) show probes for which copy number and expression were significantly correlated. The two panels in the middle show the CNA
frequencies for the group 1 (resp. for the group 2). Most of the correlations between GE and CGH were found in group 1. Gene set enrichment
analysis (GSEA) plot comparing group 1 GE profile to the signatures described for adult type gliomas. Group 1 gene expression profiles were enriched
for proneural genes (Panel E) while group A gene expression profiles were enriched for mesenchymal genes (Panel F).
doi:10.1371/journal.pone.0030313.g002
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transcriptome database of Cahoy et al [33]. Tumors of group 1
DIPG were enriched with the gene signature of mature
oligodendrocytes and to a lower extent with the one of
oligodendrocyte precursor cells (OPC), ressembling in this respect
to the proneural class of GBM glioblastoma (Figure 6). Conversely
tumors of group 2 DIPG were enriched with the gene signatures of
astrocytes and cultured astroglia (Figure 6). This later group of
DIPG shared in this respect the GE signatures of the mesenchymal
and classical classes of GBM that were enriched with the gene list
of cultured astroglia and astrocytes, respectively.
Discussion
In this study, we report the first comprehensive genomic analysis
of DIPG samples taken at diagnosis, and identify key biological
features which distinguish them from other pediatric supratento-
rial HGG. The gene expression signatures associated with the
location of a tumour was associated with differential reprogram-
ming of embryonic signaling organizers, reflecting the discrete
developmental origins of HGG presenting in different locations in
the brain. Furthermore, our data indicate that DIPG arise from
two distinct oncogenic pathways. The first group of DIPG exhibits
an oligodendroglial phenotype associated with PDGFRA gain/
amplification. Its gene expression profile is enriched for the
proneural and PDGFRA-amplified glioma signatures. It comprises
the most clinically aggressive tumours, independent of histological
grade. The second group of DIPG exhibits a mesenchymal and
pro-angiogenic phenotype orchestrated by a similar transcriptional
module to that recently described in adult glioblastomas. These
data greatly prolong our understanding of the molecular
pathogenesis of pediatric DIPG and HGG, and have significant
implications the future clinical management of children with these
tumours.
DIPG Represent a Biologically Distinct Group of HGG in
Children
Pediatric DIPG and supratentorial high-grade gliomas, al-
though harboring overlapping patterns of chromosomal imbal-
ances, could be clearly differentiated through their gene expression
signatures. Among the most differentially expressed genes with
respect to tumour location, we identified numerous homeobox and
HLH genes that were associated with brainstem tumours, and
likely represent embryonic signaling organizers that have under-
gone transcriptional reprogramming during oncogenesis. The
concept of location driving tumorigenesis in the brain [34] has
been applied to other tumor types like ependymoma [35–38] and
pilocytic astrocytomas [39], where developmentally-restricted gene
expression signatures could be related to the site of tumor growth.
Interestingly, genes found to be overexpressed in DIPG compared
to supratentorial HGG, such as LHX2 and IRX2, have been
previously described to be overexpressed in posterior fossa
pilocytic astrocytomas and ependymomas compared to their
supratentorial counterparts [36,38,39]. The converse may also
be true, with FOXG1 and ZFHX4 found to be upregulated in
supratentorial HGG compared with DIPG, similar to data from
ependymomas and pilocytic astrocytomas [36,38,39]. This
suggests that there may be a common gene expression pattern
related to the location and developmental origin of glial tumors
irrespective of the histological diagnosis. Moreover, among the
genes whose expression distinguished DIPG from the HGG in
other location, we identified several genes involved in the SHh
pathway such as PTCH1, GLIS1, GJA1, SLC1A6, KCND2,
PENK, GAD1 (see Table S2) already shown to be upregulated in
mouse models [40]. This is in line with data from Monje et al. who
have recently shown the possible role of the Sonic Hedgehog
pathway in the oncogenesis of DIPG [41].
Of particular significance was the similarity of gene expression
profiles of HGG arising in the midline/thalamus with DIPG, and
their distinction from hemispheric tumours, likely indicating
expansion from closely-related precursor populations, in these
tumours for which the cell(s) of origin are yet not known. Although
the adoption of different treatment strategies for DIPG and
supratentorial HGG is well-established in clinical practice, the
biological resemblance of midline/thalamic tumors and DIPG
raises questions regarding the management of these specific
neoplasms, currently focused on strategies designed for supraten-
torial HGG [42].
Mesenchymal transition with a stem cell-like phenotype
is the hallmark of a subset of DIPG
While a mesenchymal phenotype appears only infrequently
represented in pediatric supratentorial HGG [8], almost half of the
pediatric DIPG were characterized by the overexpression of
biomarkers of mesenchymal transition, stemness and a hypoxia-
induced angiogenic switch. The transcriptional module driving the
mesenchymal gene expression signature in adult glioblastoma [25]
was also specifically overexpressed in this group compared to the
proneural group. The acquisition of a mesenchymal phenotype
[43], stemness [44], as well as the expression of hypoxia-related
genes [45,46] have been associated with resistance to treatment
including radiotherapy. The enhanced self-renewing capability of
this subtype of DIPG further points to a distinct development
lineage from the more differentiated PDGFRA-driven DIPG. In
this respect, the higher expression of STAT3 in the mesenchymal
type of DIPG compared to the proneural one may play a key role
in their opposite differentiation. Indeed, STAT3 elimination
promote neurogenesis and inhibit astrogenesis in neural stem cell,
ie the phenotype of group 1 DIPG [47]. Glioma stem cells are
associated with a perivascular niche, and appear to modulate
vascular proliferation via VEGF, itself regulated via the HIF
pathway. These three phenomenons are closely interrelated in
Figure 3. Description of the mesenchymal type of DIPG. DIPG from group 2 gene expression profile was enriched with genes involved in
mesenchymal transition, angiogenesis and stem cell maintenance. Panel A: Heatmap of the transcription factors linked with mesenchymal gene
expression signature (MGES) in adult glioblastomas. Biomarkers of mesenchymal phenotype (VIM, CHI3L1 and TNC) and the two master regulators of
epithelio-mesenchymal transition, SNAIL1 and SNAIL2/SLUG were added to the list provided by Carro et al (Carro et al., 2010). Panel B: Boxplots
comparing the 7 transcription factors driving the MGES in adult glioblastomas (Carro et al., 2010) in the two groups of DIPG (group 1 in cyan, group 2
in purple). Relative expression in log2 ratio compared to normal brainstem control is indicated. Vimentine immunohistochemistry in tumors of group
2 shows the positivity of tumors cells (Panel C) while in group 1 only vessels and reactive astrocytes were positive (Panel D). Panel E: Spearman
correlation of the expression of SNAI2 and VEGFA. Group 1 tumors (cyan dots) segregate clearly from tumors of group 2 (purple dots). Panel F:
Spearman correlation of the expression of CHI3L1 and VEGFA. Group 1 tumors (cyan dots) segregate clearly from tumors of group 2 (purple dots).
Panel G: Gene expression of stem cell and mesenchymal markers in DIPG tumorospheres derived from primary tumors of patients in stem cell
medium as previously described (Thirant et al, 2011). Quantitative RT-PCR (qPCR) were performed using normal brain cortectomy as control. The
spheroids cultured from three different DIPG were compared to normal neural stem cells (NSC) grown as neurospheres in the same medium.
doi:10.1371/journal.pone.0030313.g003
Integrative Genomics of Pontine Gliomas
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e30313several cancers including glioblastoma [48–51], and open the
possibility that agents which target angiogenesis and/or drive
differentiation of tumour stem cells may find application in this
subset of DIPG to increase the antitumor effects of ionizing
radiation.
Despite the involvement of Ras pathway in epithelio-mesen-
chymal transition via SNAI2 [52] and its link with worse outcome
of pediatric HGG [53], we did not find a correlation between H-
RAS gain/amplification and its gene expression, nor activating
mutations in the RAS genes including BRAF V600E already
described in some pediatric supratentorial gliomas [27], again
highlighting differential oncogenic mechanisms in DIPG com-
pared to other pediatric HGG.
Proneural and oligodendroglial differentiation associated
with PDGFRA amplification
We have identified through unsupervised gene expression
clustering a group of DIPG characterized by a ‘proneural’
Figure 4. Description of the oligodendroglial/proneural type of DIPG. Panel A: Radial plot showing the expression of oligodendroglial
markers in the two groups of DIPG, in log2 ratios related each other. The red circle represent the median expression level of the whole population of
DIPG. Group 1 expresses higher levels of oligodendroglial markers than group 2 DIPG. Panel B: Morphological oligodendroglial differenciation in
group 1 tumors (HES staining, 640). Panel C: Morphological astrocytic differenciation in group 2 tumors (HES staining 640). Panel D: Olig2
immunohistochemistry in a group 1 DIPG showing that probably not all cells in the biopsy are tumoral (640). Panel E: Dual immunohistochemistry for
Olig2 and GFAP showing that tumor cells in mitosis are GFAP negative but Olig2 positive (6100). Panel F: Overall survival of 55 DIPG according to the
presence (red) or absence (blue) of oligodendroglial differenciation. Median OS was shorter in patients with oligodendroglial type of tumors (7.73 vs
12.37, p=0.045, log rank test).
doi:10.1371/journal.pone.0030313.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e30313Figure 5. PDGFRA amplification/mutation is driving the oncogenesis of the oligodendroglial/proneural type of DIPG. Panel A: GSEA
graph showing the enrichment of group 1 DIPG for the gene set describing the gene expression profile of PDGFRA amplified glioblastomas. Panel B:
PDGFRA immunohistochemistry in the infiltrative part of a DIPG. Panel C: PDGFRA immunohistochemistry in the tumoral part of a DIPG. Panel D: FISH
analysis of a DIPG using a FIP1L1/PDGFRA probe showing the amplification of the locus encompassing the two genes (most frequently seen). Panel E:
Dual-FISH analysis of a DIPG with two probes one for PDGFRA and one for MET showing that the two oncogenes may be gained/amplified in
different cells within the tumor. Panel F: Integrative genomic analysis using DR-Integrator (R package). Seven genes are present in the minimal
common region (MCR) gained on chromosomal location 4q12 in DIPG. Boxplots represent the distribution of GE data and circles represent CNA data.
The circles are centered on the corresponding GE measure on the distribution and their radii are proportional to the absolute value of CNA, red ones
being losses and green ones gains. CNA and GE were highly correlated for four of these seven genes (CHIC2, KIT, KDR, PDGFRA). Panel G: Diagram of
the PDGFRA gene showing the mutations discovered in DIPG samples and xenografts.
doi:10.1371/journal.pone.0030313.g005
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amplifications/mutations. Moreover, the gene expression profile
of group 1 DIPG was significantly enriched with genes describing
the signature of PDGFRA amplified gliomas [8,24] supporting the
hypothesis that PDGFRA amplification is associated with a robust
gene expression profile across tumor location and patient’s age.
This association has been previously described in adult tumors
[43,54–56], and include the expression of genes involved in
neurogenesis and oligodendrocyte development, such as Olig
transcription factors, Nkx2.2, PDGFRA and SOX10 [57]. DIPG
with oligodendroglial phenotype and Olig2 overexpression
exhibited an even worse evolution and resistance to radiation
than the other DIPG in our series. This could be explained by the
recent findings that the central nervous system-restricted tran-
scription factor Olig2 opposes p53 response to genotoxic damage
in neural progenitors and malignant glioma [58]. This is however
in contrast with the adult gliomas where oligodendroglial
differentiation and proneural phenotype are linked with a better
prognosis [24]. Moreover, we did not observe IDH1/2 mutation
in 10 DIPG [59] while in adult proneural gliomas IDH1 mutations
are frequent [24]. In pediatric gliomas, IDH1/2 mutations are
almost exclusively seen in adolescents [59,60] who indeed do not
represent the target population of DIPG. The presence of IDH1
mutation in tumors from adolescents was not correlated with an
oligodendroglial phenotype in our cohort of pHGG previously
published [59]. Together with the fact that the group 1 DIPG is
enriched preferentially with the signature of mature oligodendro-
cytes rather than oligodendrocyte progenitor cells, these data
could suggest that this group of DIPG could be developed from a
different oligodendroglial cell than their adult counterpart. This
would be in line with the rarity of 1p19q co-deletion in pediatric
gliomas with oligodendroglial features.
Integrative genomics showed that the gene expression of this
group of DIPG was driven by copy number changes on the
contrary to the other DIPG suggesting that chromosomal
instability plays an important role in the phenotype of these
tumors. Conversely, gene expression in the other group of DIPG
may be more driven by epigenetic changes.
We found 28% (9/32) of PDGFRA gains or amplifications, all
but one being included in the group 1 defined by unsupervised
gene expression clustering. The PDGF autocrine/paracrine loop
has been frequently implicated in oligodendrogliomas [61] and has
been used to create preclinical models of glioma [62,63], including
brainstem tumors [64,65]. PDGFRA amplification has been
shown to be more frequent in pediatric HGG than in adult ones
[8] and a recent report found PDGFRA gain or amplification in
four out of eleven post-mortem samples of DIPG [10]. In one of
our previous study, PDGFRA protein was also more frequently
detected by IHC in DIPG than in other pediatric HGG [20].
We identified 10% of pediatric DIPG to harbor PDGFRA
missense mutations, considerably more frequently than the 2/206
(1%) reported in adult GBM (http://tcga-data.nci.nih.goc/docs/
publications/gbm_exp/). These mutations were located in exons
coding for the extracellular domains of the protein, potentially
disrupting ligand interaction, but not in the tyrosine-kinase
domain. Their oncogenic role can be suspected, especially as they
are found exclusively in concert with gene amplification. Similarly,
mutations have been found in the ectodomain but not in the
tyrosine-kinase domain of EGFR gene in adult GBM [66]; these
mutations were shown to be oncogenic. Moreover, similar to
EGFRvIII mutants, deletions in the extracellular domain of
PDGFRA have been already reported in as many as 40% of
glioblastomas with PDGFRA amplification and were associated
with increased tyrosine-kinase activity [67]. Unfortunately, the
Figure 6. Comparison of gene expression signature of the two DIPG groups with specific neural lineages. A GSEA analysis was
processed using the gene list previously described by Lei et al [32] and derived from the gene sets specifically enriched in astrocytes,
oligodendrocytes, neurons, oligodendrocytes progenitors cells and cultured astroglial cells. Heatmap of the enrichment scores of each DIPG samplei s
represented with a red to blue color scale shows the range from the highest to lowest enrichment score.
doi:10.1371/journal.pone.0030313.g006
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the possibility of in frame deletions and this would need further
analysis on new samples.
Translational implications of targeting genomic
alterations in DIPG
Lack of insight into disease mechanisms impeded the develop-
ment of effective therapies in DIPG for years, with the selection of
therapeutic agents to be used in conjunction with irradiation
determined empirically or based on their efficacy in adult high-
grade gliomas. Changing the paradigm of the treatment of this
disease requires a better understanding of the key biological events
driving this type of neoplasm. Our clinical and biological program
allowed us to discover new potential therapeutic targets previously
overlooked or ignored. For the first time, rationale design of trials
with targeted therapies could be implemented in the armentarium
against these aggressive neoplasms. PDGFRA indeed seems to be
the most exciting target given also the existence of several
inhibitors with a known toxicity profile in children, including
patients with DIPG at relapse [20] or at diagnosis after irradiation
[68]. Despite significant drug concentrations reached inside the
glioblastoma [69], imatinib has shown limited efficacy in recurrent
or newly diagnosed glioblastoma in adults [70] and response to the
drug was not increased in patients with PDGFRA immunoposi-
tivity [71]. No information on the histology of the brainstem
tumors was available in the Pediatric Brain Tumor Consortium
(PBTC) phase II trial of imatinib [68] where most of the patients
with brainstem gliomas received indeed the drug after the
completion of their radiotherapy schedule. In a recent study of
the ‘Innovative Therapies in Children with Cancer’ consortium,
where imatinib was only given to patients with proven PDGFRA,
PDGFRB or KIT over expression determined by immunochem-
istry [20], one child with recurrent DIPG harboring PDGFRA
expression in 50% of the cells in the biopsy showed a sustained
objective response (minus 31% for tumor size) for a period of ten
months. Identifying the key predictive markers for efficacy of
targeted agents will be a vital step in translating genomic data to
the clinic, particularly where specific activating mutations are
identified. The literature [70,71] indicates however that the effect
of imatinib as single agent is limited and that combination with
other agents such as irradiation should be considered [72,73]. In
addition, insufficient drug penetration in the brain and in some
part of the tumor may explain these disappointing results.
Enhanced delivery would then need either blood to brain barrier
opening [74] or P-gp and ABCG2 inhibition [75]. In this respect
the DIPG orthotopic models newly described [63,64] will be
valuable tools to study the appropriate way to deliver these drugs
in addition to help our understanding of the disease. Combina-
torial targeted approaches may also be valid given the observation
of multiple oncogenic alterations activating the same downstream
signaling cascades [76]. Our finding of simultaneous amplification
of PDGFRA and MET in a subset of DIPG, for example, may
justify the use of multikinase inhibitors or combinations of TKI, as
has been demonstrated for pediatric glioblastoma cells in vitro [77].
Our integrated genetic profiling of diagnostic DIPG has
identified two biologically and clinically distinct groups of DIPG,
with clear differences from hemispheric HGG, and with likely
differential treatment strategies warranted. These data highlight
the importance of biologically driven guidance for novel
therapeutic intervention in these currently untreatable tumors,
and argue for the systematic biopsy of these lesions in order to
facilitate this, in addition suggesting that some supratentorial deep-
seated infiltrating HGG of the deep grey nuclei may deserve a
similar approach.
Materials and Methods
Tumor and Nucleic Acids extraction
Tumor samples and clinical information were collected with
written informed consent (see Supporting Information S1) of the
parents/guardians before inclusion into protocols approved by the
Internal Review Board of the Necker Sick Children’s Hospital in
Paris and the Gustave Roussy Cancer Institute in Villejuif
[corresponding to two phase I/II trials, see references 20 and
21]. Only patient with classical diagnostic features of DIPG were
included: 1) short clinical history of less than three months, 2)
infiltrating neoplasm centered on the pons and involving at least
50% of the anatomical structure, 3) histology excluding a pilocytic
astrocytoma or ganglioglioma.
Tumor biopsies were snap frozen in liquid nitrogen in the
operating room to ensure preservation of high quality RNA,
ground to powder and then RNA and DNA were extracted
following two different protocols according to their respective
efficiency: Rneasy Micro Kit (Qiagen) and/or TRIzol reagent
(Invitrogen).
Microarray Analyses
DNA and RNA microarray hybridizations were carried out by
the Functional Genomics Platform of the Integrated Research
Cancer Institute in Villejuif (http://www.igr.fr/en/page/integrated-
biology_1529) using the Agilent 44 K Whole Human Genome
Array G4410B and G4112F, respectively (http://www.agilent.
com). The microarray data related to this paper are MIAME
compliant and the raw data have been submitted to the Array
Express data repository at the European Bioinformatics Institute
(http://www.ebi.ac.uk/arrayexpress/) under the accession number
E-TABM-1107.
Bioinformactic Analyses
Raw copy number ratio data were transferred to the CGH
Analytics v3.4.40 software for further analysis with the ADM-2
algorithm (http://www.agilent.com). A low-level copy number
gain was defined as a log 2(ratio) .0.3 and a copy number loss was
defined as a log 2(ratio) ,20.3. A high-level gain or amplification
was defined as a log 2(ratio) .1.5. Minimum common regions
(MCR) were defined as chromosome regions that show maximal
overlapping aberrations across multiple samples with the STAC
v1.2 software [78]. Probe-level measurement MCRs do not
include all genes that are altered within a given aberrant region
in a particular tumor but define the recurrent abnormalities that
span the region.
Raw gene expression data using normal brainstem as reference
were transferred into R software for statistical analysis. In order to
discover groups in GE data set, the k-means algorithm from R
software has been run for two to five groups on the entire dataset.
Then for each clustering the BIC value was calculated, according
to Guillemot et al [22], in order to determine the best one, which
was the one with two groups. GSEA analysis [23] was performed
with the pre-ranked tool on gene list ranked by increasing FDR
adjusted p-values, for each contrast of interest, with default
parameter values. A nominal False Discovery Rate (FDR) of
,0.25 was considered statistically significant for GSEA. We ran
GSEA analysis with t-test option as metric parameter.
For integrative genomics analysis, we used the DR-Integrator
package for R [79].
Fluorescent In Situ Hybridization
FISH was performed from formalin-fixed-paraffin-embedded
(FFPE) tumor samples or frozen tumor touch slides for the
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LSI EGFR (Vysis/Abbot) were used according to the manufac-
turer’s instructions. PDGFRA and MET probes were labelled
from BAC-clones RP11-58C6 and RP11-819D11 (PDGFRA) and
RP11-165C4 and RP11-951I21 (MET) using the Bioprime kit
(Invitrogen) and DIG-6-dUTP (Roche). Slides were pre-treated in
0.2 M HCl, 8% sodium thiocyanate and 0.025% pepsin. Probes
were hybridised overnight at 37C. Slides were washed and
incubated with conjugates streptavidin-Cy3 (Invitrogen) and anti-
DIG-FITC (Roche).
Mutation screening of selected genes
For direct sequencing, the exon 15 of BRAF and all the
individual exons of PDGFRA were PCR amplified using Taq DNA
polymerase (Invitrogen) and primers that can be provided upon
request. PCR products were sequenced with BigDye v3.1 and run
on an AB3730 genetic analyser (Applied Biosystems). Traces were
analysed using Mutation Surveyor software (Softgenetics). The
effect of the mutations on the protein structure was predicted using
Polyphen (http://genetics.bwh.harvard.edu/pph/) and SIFT
(http://sift.jcvi.org/) databases.
Histology and Immunohistochemistry on Primary Tumor
Material
Tumor histology was reviewed by PV. Tumors were classified
and graded according to the 2007 WHO classification. Repre-
sentative formalin-zinc (formol 5%; Zinc 3 g/L; sodium chloride
8 g/L) fixed sections were deparaffinized and subjected to a
Ventana autostainer (BenchMark XT, Ventana Medical system,
Tucson, USA) with a standard pretraitement protocol included
CC1 buffer for MIB (KI-67) and P53. A semi-automatised system
using a microwave antigen retrieval (MicroMED T/T Mega;
Hacker Instruments & Industries, Inc., Winnsboro, SC) for
30 minutes at 98uC (manufacturer recommendations) and the
RTU Vectastain Universal detection system (Vector laboratories,
Burligame, CA, USA) for Olig2. Sections were then incubated
with various commercial monoclonal primary antibodies against
Olig2 (AF 2418, 1/150, R/D system, CA, USA), P53 (DO-1, 1/1,
Ventana) and MIB-1 (1/100; Dako, Glostrup, Denmark).
Diaminobenzidine was used as the chromogen. A minimal
threshold at 10% of the total stained tumor cells served as a cut-
off for defining the p53-positive status. A MIB-1 labeling index
(MIB-1 LI) was obtained by counting the number of MIB-1-
positive tumor cells in regions with the maximum number of
labeled tumor cells. Ten microscopic high-power field sets were
counted, and the MIB-1 LI was computed as a percentage of
immunopositive cells from the total cells counted in selected fields.
Light microscopic images were digitally captured using a Nikon
eclipse E600 microscope (Nikon, Tokyo, Japan) equipped with
Nikon DXM 1200 Digital camera. Photomicrographs were
assembled for illustrations using the Adobe Photoshop version
7.0.1 software (Adobe, San Jose, California, USA).
Supporting Information
Figure S1 DIPG are different from supratentorial high-
grade gliomas in children. Panel A: example of a biopsy
sampling in a patient with DIPG. A maximum of 8 core
biopsy samples can be obtained per patient. Panel B: heatmap
of the unsupervised hierarchical clustering of 29 DIPG.
From the 32 available samples, two had a completely flat profile
and one was of unsufficient quality. The analaysis was then run on
29 samples. Gains are represented in green (the intensity being
correlated to the log2ratio) and amplifications as blue dots. Losses
are represented in red (the intensity being correlated to the
log2ratio). The lower panel indicate the general profile of genomic
imbalances encountered in the 32 samples, y axis scale being the
frequency of the aberrations. The colored right panel shows the
profile of each individual sample and the black & white right panel
shows the percentage of the genome with imbalances. C: overall
survival of the patients with CGHarray data according
to the loss or the persistence of the TP53 locus. Overall
survival was significantly lower in patients with TP53 gene loss
(p=0.01, log-rank test). D: principal component analysis
(PCA) of pediatric high-grade gliomas (HGG) CGHarray
data irrespective of their location. Hemispheric HGG are
indicated in yellow, midline HGG are indicated in grey and
brainstem HGG or DIPG are indicated in pink. All the probes
passing the quality control were used for the analysis. E: box-
plots comparing the expression of some of the key
regulators of brainstem embryogenesis in DIPG (pink)
and supratentorial HGG (yellow). The adjusted p-value of
the comparison is given in the upper left corner of each panel. All
values are given relative to the expression found in normal adult
brainstem.
(TIFF)
Figure S2 DIPG comprises two biological subgroups
with distinct survival and pathological characteristics.
A: Identification of the most optimal Bayesian Informa-
tion Criterion (BIC) value. The most optimal BIC value was
obtained using the class prediction algorithm of Guillemot et al.
(BIOTECHNO’08). The graphs show that the accuracy of class
prediction did not improve with increasing number of groups. B:
Integrative analysis of genomic and gene expression
data. When considering all DIPG samples from whom both GE
and CGHarray data were available, the expression of 1460 genes
(ie 6% of the genome) was significantly correlated with copy
numbers. The cheese-plots of the 20 genes with the highest
correlation are provided. Complete data set is available upon
request.
(TIFF)
Figure S3 Mesenchymal transition and a pro-angiogen-
ic switch define a subset of DIPG. A: The master
epithelial to mesenchymal transition regulators, SNAI1
and SNAI2/Slug are upregulated in a subset of DIPG.
The box-plots of the two DIPG subgroups identified are shown in
purple and brown respectively. Gene expression are given
compared to normal adult brainstem. The p-value is indicated
for each gene in the upper right corner of the panel. B:
Angiogenic markers are overexpressed in a subgroup
of DIPG. The two different subgroups of DIPG are represented
in purple and light green. The p-value is indicated for each gene in
the upper right corner of the panel. Gene expression are given
compared to normal adult brainstem. C: Stem cell markers
are overexpressed in a subgroup of DIPG. The two
different subgroups of DIPG are represented in purple and cyan.
The p-value is indicated for each gene in the upper left corner of
the panel. Gene expression are given compared to normal adult
brainstem. D: Gene expression profiling of one of the
DIPG stem cell cultures. Principal component analysis of one
of the DIPG stem cell cultures together with all the primary DIPG
samples.
(TIFF)
Figure S4 Amplification of multiple RTK in the same
tumor. Example of a DIPG sample for which simultaneous
amplification of PDGFRA and EGFR could be observed by FISH.
(TIFF)
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